Pluri (PLUR) Competitors $4.95 -0.46 (-8.50%) Closing price 03:34 PM EasternExtended Trading$4.66 -0.29 (-5.86%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. CYBN, VYGR, IMAB, ACOG, LFVN, DERM, IPHA, ENTA, SPRO, and NVCTShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cybin (CYBN), Voyager Therapeutics (VYGR), I-Mab (IMAB), Alpha Cognition (ACOG), Lifevantage (LFVN), Journey Medical (DERM), Innate Pharma (IPHA), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Cybin Voyager Therapeutics I-Mab Alpha Cognition Lifevantage Journey Medical Innate Pharma Enanta Pharmaceuticals Spero Therapeutics Nuvectis Pharma Pluri (NASDAQ:PLUR) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Does the media refer more to PLUR or CYBN? In the previous week, Cybin had 2 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Cybin and 0 mentions for Pluri. Pluri's average media sentiment score of 1.87 beat Cybin's score of 0.69 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Very Positive Cybin Positive Do institutionals & insiders believe in PLUR or CYBN? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 25.9% of Pluri shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is PLUR or CYBN more profitable? Cybin has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Cybin's return on equity of -37.58% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Cybin N/A -37.58%-36.59% Which has higher valuation and earnings, PLUR or CYBN? Pluri has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K118.05-$20.89M-$5.53-0.90CybinN/AN/A-$57.88M-$3.88-2.14 Do analysts recommend PLUR or CYBN? Pluri currently has a consensus price target of $12.00, indicating a potential upside of 142.42%. Cybin has a consensus price target of $85.00, indicating a potential upside of 921.63%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more volatility & risk, PLUR or CYBN? Pluri has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummaryCybin beats Pluri on 10 of the 15 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.58M$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E RatioN/A19.8828.0419.84Price / Sales118.05305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book4.957.678.125.65Net Income-$20.89M-$55.28M$3.25B$258.00M7 Day Performance-6.78%2.50%0.97%2.09%1 Month Performance14.85%11.70%7.36%11.13%1 Year Performance-10.81%4.89%31.31%18.40% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.5764 of 5 stars$4.95-8.5%$12.00+142.4%-5.6%$42.58M$330K-0.90150Positive NewsGap DownCYBNCybin2.8641 of 5 stars$7.70-2.2%$86.00+1,017.5%N/A$176.13MN/A-1.7550News CoverageVYGRVoyager Therapeutics4.0186 of 5 stars$3.15+3.6%$13.39+325.1%-63.1%$173.82M$80M-2.15100News CoverageIMABI-Mab2.871 of 5 stars$2.13+1.7%$6.00+182.4%+42.1%$173.53M$3.89M0.00380News CoverageACOGAlpha Cognition1.7412 of 5 stars$10.75-4.4%$20.00+86.0%N/A$172.22MN/A-8.96N/ALFVNLifevantage4.2541 of 5 stars$13.43-1.2%$30.50+127.1%+107.6%$169.02M$200.16M19.46260News CoverageDERMJourney Medical2.265 of 5 stars$7.23+1.8%$9.50+31.4%+27.4%$165.55M$56.13M-18.2290IPHAInnate Pharma2.3347 of 5 stars$1.79-1.6%$11.00+514.5%-18.0%$165.00M$21.77M0.00220News CoverageGap UpENTAEnanta Pharmaceuticals3.7724 of 5 stars$7.77-1.5%$18.00+131.7%-54.3%$164.26M$67.64M-1.69160Positive NewsSPROSpero Therapeutics3.9397 of 5 stars$2.94+1.2%$5.00+70.4%+67.6%$164.10M$47.98M-2.29150Positive NewsNVCTNuvectis Pharma3.2049 of 5 stars$7.82-0.4%$17.00+117.5%+17.4%$163.36MN/A-6.928Positive News Related Companies and Tools Related Companies Cybin Competitors Voyager Therapeutics Competitors I-Mab Competitors Alpha Cognition Competitors Lifevantage Competitors Journey Medical Competitors Innate Pharma Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Nuvectis Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.